Business Wire

Tetra Pharm Technologies Prescribes Rootstock ERP to Drive Its Digital Strategy

Share

Danish biopharmaceutical company to utilize Rootstock and Salesforce to enable end-to-end data visibility, improve decision-making, and support growth

Rootstock Software today announced that Tetra Pharm Technologies, a Danish biopharmaceutical company specializing in chronic pain, mental health, and obesity treatments, has selected Rootstock ERP to advance the digital strategy around its manufacturing operations. As a young and rapidly expanding company, Tetra Pharm Technologies is leveraging Rootstock ERP as part of its foundation for growth.

Founded in 2018 by industry veterans Martin Rose and Jesper Breum, Tetra Pharm Technologies is dedicated to improving quality of life for patients through innovative science. With a strong focus on treatments targeting the central nervous system (CNS) and the immune system to treat neurological diseases and psychiatric disorders, the company has grown steadily since its inception. In 2020, Tetra Pharm Technologies opened its first production site in Hillerød and received authorization from the Danish Medicines Agency.

“We saw the importance of putting the right ERP system in place early, before any of our processes became set in stone,” said Steen Jakobsen, Chief Financial Officer of Tetra Pharm Technologies. “We are growing quickly and need tools that will allow us to scale efficiently. After a thorough review of ERP options, we found that Rootstock ERP on the Salesforce Platform offered the best fit with our innovative culture and business needs. Rootstock’s flexibility and seamless integration with Salesforce Sales Cloud will enable us to automate processes and ensure we’re positioned to meet the regulatory requirements of our upcoming clinical trials and potential market expansions.”

“Tetra Pharm Technologies needed a robust ERP solution to provide traceability, help control inventory, and manage costs effectively,” said Nicolai Lyster, Supply Chain Manager at Tetra Pharm Technologies. “Rootstock’s QuickStart Implementation gives us the flexibility to control the pace and depth of our deployment without heavily relying on consultants—a model we haven’t seen with other ERP providers. The Rootstock Success Community has also been a great resource, offering accessible training and support. As we scale, we’re excited about Rootstock’s ability to evolve with our company, offering opportunities to extend our capabilities.”

Tetra Pharm Technologies is leveraging Rootstock’s Learning Center and QuickStart Implementation to support user adoption and a rapid go-live. Using the Rootstock Configuration Wizard, the company is focusing on deploying core financial and operational processes.

“Tetra Pharm Technologies’ decision to implement Rootstock underscores the value of our ERP solution in highly regulated and complex industries like life sciences,” said Rick Berger, CEO of Rootstock Software. “We are excited to work closely with Tetra Pharm Technologies to enhance their manufacturing processes and scale their operations to bring their treatments to market.”

Tetra Pharm Technologies also anticipates that the implementation of Rootstock ERP will significantly reduce its reliance on spreadsheets and manual processes, enabling more accurate reporting, better real-time visibility, and improved decisions in its business.

For more information on how Rootstock ERP helps companies to streamline their manufacturing operations and support growth, schedule a demo today or meet the company at one of its upcoming events.

Salesforce, Sales Cloud, AppExchange, and others are among the trademarks of Salesforce, Inc.

About Rootstock

Rootstock Software provides the leading ERP for product companies, empowering manufacturers, wholesalers, and distributors to turbocharge their operations. Natively built on the Salesforce Platform, Rootstock is a modern, future-proof ERP with a fresh user experience. Customers appreciate Rootstock’s focus on their success—providing AI-ready decisioning capabilities but with a human-first approach. IT teams value Rootstock’s platform as it minimizes the need to coordinate complex customizations and third-party integrations. All of this adds up to delighted customers. As Rootstock continues to grow, stay tuned to hear about its new customers, career opportunities, and LinkedIn posts.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114198426/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Global Cell and Gene Therapy Trials: Driving Innovation in Oncology and Beyond14.11.2024 14:05:00 CET | Press release

Novotech, the global full-service clinical Contract Research Organization (CRO), has published its latest whitepaper, offering in-depth analysis and emerging trends and advancements within the rapidly evolving field of cell and gene therapies. The report provides critical insights into the growth of clinical trials, innovations and strategic opportunities, shaping the future of this field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114441933/en/ Key Highlights from the Report:Global Clinical Trial Expansion: Over 1,500 drug candidates in development across phases 0 to III. CAR-T therapies account for 32% of the pipeline, primarily targeting hematological cancers. The global trial landscape experienced a 32.5% growth from 2019 to 2023, with Asia-Pacific leading in trial activity (44% of all trials). Oncology Focus: CAR-T and CAR-NK therapies represent ~30% of all cell and gene trials, with a strong focus on solid and h

REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202414.11.2024 13:52:00 CET | Press release

All economic indicators have substantially improved:Consolidated turnover of €1,666.9 million (1,548.0 as at 30 September 2023)EBITDA of €275.5 million (235.8 as at 30 September 2023)EBIT of €224.2 million (187.7 as at 30 September 2023)Pre-tax profit of €216.0 million (170.3 as at 30 September 2023)Positive Net Financial Position of €312.6 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2024. The Group's consolidated turnover in the first nine months of the year reached €1,666.9 million, an increase of 7.7% compared to €1,548.0 million recorded on 30 September 2023. The indicators for the period are positive. Consolidated EBITDA was €275.5 million, equal to 16.5% of the consolidated revenues. As of September 2023 EBITDA was €235.8 million. EBIT, from January to September, reached €224.2 million, equal to 13.4% of the consolidated revenues. The corresponding 2003 figure was €187.7 million. Pre-tax profit, from January to Septembe

Experian Named to World’s Best Workplaces™ 2024 by Fortune and Great Place to Work®14.11.2024 13:22:00 CET | Press release

Recognition honours top 25 companies building the best workplace cultures in the world Experian today announced it was named one of the World’s Best Workplaces™ 2024 by Fortune and Great Place to Work®, which recognises a select 25 global companies that are building the best workplace cultures in the world. The honour highlights Experian’s people-first workplace culture that promotes inclusivity, fosters collaboration and innovation, and prioritises team member well-being, personal growth, and advancement. In its 14th year of producing this prestigious international list, Great Place To Work® surveyed 6.2 million employees worldwide on key factors that create great workplaces and analysed company workplace programmes that impact 18 million employees globally. Organisations were assessed on their efforts to create great workplaces and positively impact people and communities across multiple countries around the world. “This is a great recognition,” said Brian Cassin, Chief Executive Off

Rogers Investment Advisors leads FSR Angel 1 LPS investment in XELA Robotics Expansion to Drive Global Ambitions14.11.2024 13:00:00 CET | Press release

XELA Robotics Co., Ltd., (“XELA”), a pioneer in tactile sensing and advanced tactile AI-driven robotic solutions, today announced a significant 7-digit (USD) investment by FSR Angel 1 LPS (“FSR”), managed by Rogers Investment Advisors K.K.(“RIA”). The investment reinforces XELA’s vision to expand its global footprint while maintaining its position as a leader in tactile AI technology. The founding team will remain the majority shareholders of XELA, a company spun off from Waseda University, one of Japan’s most prestigious academic institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114649471/en/ XELA Robotics CEO Alexander Schmitz with key investors from FSR Angel 1 LPS and Rogers Investment Advisors K.K., marking a pivotal step in our mission to expand globally and lead in AI-driven tactile sensing. (Graphic: Business Wire) XELA’s disruptive AI technology integrates tactile sensors to open new horizons for indus

BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer14.11.2024 12:00:00 CET | Press release

New name reflects Company’s bold vision to eradicate cancer by harnessing the transformative power of global collaboration and multisectoral partnershipsCompany will change its Nasdaq ticker to ONC BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241114671168/en/ (Graphic: Business Wire) “Cancer, a leading cause of death worldwide, exacts an immense toll on individuals, families, and communities. No person, family, scientist, clinician, hospital, policy maker, company or country can or should face this devastating disease alone. We all must work together to win, which is why we are committed to playing a critica

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye